Public Accountability Report Public Accountability Report

2023 Disease Control
Mission Statement The Office of Disease Control (ODC) administers programs to prevent and control infectious and communicable diseases, to reduce and eliminate exposure, and to ensure population health, safety, and well-being. Formerly the Office of Health Protection, ODC was born out of necessity, as during the COVID-19 pandemic IDPH’s efforts became singularly focused on disease control. The creation of ODC provides IDPH with a platform to build a significantly larger disease control and response team while maintaining appropriate span of control. These former Office of Health Protection divisions now make up ODC: Infectious Diseases; HIV/Hepatitis/STI/TB; Fiscal/Grants Management Support Services; and the Bureau of Testing, which is inclusive of statewide Public Health laboratory operations.
Program Goals and Objectives
  1. The Division of Infectious Diseases includes immunizations, communicable diseases, infectious diseases, and surveillance. Primary responsibilities include statewide surveillance, identification of disease outbreaks and clusters, reporting, and providing consultation services and training for public health partners for over 64 diseases/conditions. The Communicable Disease Section conducts surveillance and outbreak response for 72 different diseases, including COVID-19 and monkeypox.
    1. The Division of HIV/Hepatitis/STI/TB focuses on preventing the spread and complications resulting from various community diseases, specifically tuberculosis, hepatitis, sexually transmitted infections, and HIV/AIDS. The programs work with local community organizations to spread awareness, deliver education, and provide resources.
      1. The Division of Laboratories consists of our three state laboratories in Carbondale, Chicago, and Springfield. Each laboratory supports public health programs by providing accurate and timely results from environmental and clinical testing. Our laboratories respond to epidemic and pandemic outbreak response, clinical surveillance testing, environmental and dairy testing, and select agent testing in support of bioterrorism and chemical terror events. The division performs tests for a variety of high-consequence pathogens in clinical specimens and environmental food, water, and dairy samples. In addition, the Division of Laboratories performs the necessary testing of Illinois newborns for genetic and metabolic disorders. Data generated from testing at the IDPH Division of Laboratories are used for disease control, prevention, and treatment of disease, as well as in epidemiological studies. A hallmark of the work performed by the labs is the screening for newborn metabolic and genetic diseases.
        Source of Funds General Revenue Fund, State Coronavirus Urgent Remediation Emergency (State CURE) Fund, African-American HIV/AIDS Response Fund Statutory Authority 20 ILCS 2310
        Fiscal Year 2024 Target/Projected Fiscal Year 2023 Actual Fiscal Year 2023 Target/Projected Fiscal Year 2022 Actual Fiscal Year 2021 Actual
        Input Indicators
        Total expenditures - all sources (in thousands) $ 1,091,794.5 $ 427,005.5 $ 1,881,223.4 $ 634,325.0 N/A
        Total expenditures - state appropriated funds (in thousands) $ 1,091,794.5 $ 427,005.5 $ 1,881,223.4 $ 634,325.0 N/A
        Average monthly full-time equivalents 300.0 243.0 306.0 237.0 N/A
        Output Indicators
        Number of lab tests requested N/A 835,220 467,000 490,985 2,645,346
        Number of lab tests performed N/A 2,842,298 3,220,000 3,569,687 4,444,108
        Number of HCV tests performed by grantees N/A 2,808 N/A N/A N/A
        Number of GC/CT samples received 22,553 22,271 N/A 20,903 19,505
        Number of GC/CT samples rejected 200.0 130.0 N/A 193.0 127.0
        Number of GC/CT samples tested 22,353 22,141 N/A 20,710 19,378
        Number of Grade A Dairy samples received N/A N/A N/A N/A N/A
        Number of Grade A Dairy samples rejected N/A N/A N/A N/A N/A
        Number of Grade A Dairy samples tested N/A N/A N/A N/A N/A
        Number of HIV tests distributed to clients with clients reporting test results back to the agency N/A N/A N/A N/A N/A
        Number of HIV tests performed by grantee N/A 29,426 N/A N/A N/A
        Number of HIV-positive tests performed by grantee N/A 15.0 N/A N/A N/A
        Number of HIV samples received 6,687 6,654 N/A 6,173 6,378
        Number of HIV samples rejected 146.0 48.0 N/A 70.0 126.0
        Number of HIV samples tested 6,540 6,606 N/A 6,103 6,252
        Total NBS tests performed 3,103,808 3,062,602 2,800,000 3,170,828 3,210,794
        Number of disorders on NBS test panel N/A N/A N/A N/A N/A
        Number of NBS samples received N/A N/A N/A N/A N/A
        Number of NBS samples rejected N/A N/A N/A N/A N/A
        Number of NBS samples tested (samples received - samples rejected) N/A N/A N/A N/A N/A
        Number of private water samples received 4,126 4,098 N/A 4,021 3,892
        Number of private water samples rejected 573.0 499.0 N/A 563.0 452.0
        Number of private water samples tested 3,552 3,599 N/A 3,458 3,440
        Number of syphilis samples received 7,232 7,222 N/A 6,695 6,758
        Number of syphilis samples rejected 128.0 71.0 N/A 79.0 121.0
        Number of syphilis samples tested 7,104 7,151 N/A 6,616 6,637
        Outcome Indicators
        Average turnaround time for reporting GC/CT results (days) 2.0 2.0 N/A 2.0 2.0
        Number of GC/CT-positive specimens identified from testing 3,148 2,540 N/A 2,896 3,050
        Prevalence of GC/CT in tested population 14.08% 11.00% N/A 14.00% 15.70%
        Average turnaround time for reporting Grade A Dairy results (days) 2.0 N/A N/A N/A N/A
        Number of Grade A Dairy specimens identified with biological or chemical contaminates N/A N/A N/A N/A N/A
        Prevalence of Grade A Dairy contaminates in tested population N/A N/A N/A N/A N/A
        Average turnaround time for reporting HIV results (days) 2.0 2.0 N/A 2.0 2.0
        Number of HIV-positive specimens identified from testing 108.0 107.0 N/A 103.0 97.0
        Prevalence of HIV in tested population 1.66% 2.00% N/A 1.70% 1.60%
        Percentage of NBS tests reported N/A 100.00% 100.00% 100.00% 100.00%
        Average turnaround time for reporting NBS results (days) 7.0 7.2 N/A 7.1 8.8
        Number of NBS disorders identified from testing 20,534 19,430 N/A 22,202 24,174
        Prevalence of NBS disorders in tested population (number of disorders identified / total number of NBS tests performed) 0.66% 0.63% N/A 0.70% 0.75%
        Average turnaround time for reporting private water results (days) 2.0 3.0 N/A 5.0 6.0
        Number of private water specimens identified with bacterial contaminates 1,632 1,531 N/A 1,630 1,515
        Prevalence of private water contaminates in tested population 45.95% 43.00% N/A 47.10% 44.00%
        Average turnaround time for reporting syphilis results 2.0 2.0 N/A 2.0 2.0
        Number of syphilis-positive specimens identified from testing 839.0 811.0 N/A 616.0 543.0
        Prevalence of syphilis in tested population 11.81% 11.00% N/A 9.30% 8.20%
        Newly diagnosed Index patients reported to the Partner Services Program 100.00% 100.00% 100.00% N/A N/A
        External audit: percentage Clinical Lab Improvement Amendments (CLIAs) N/A 85.00% 100.00% 70.00% 85.00%
        Internal audit: percentage of timely QA documentation N/A 100.00% 100.00% 100.00% 100.00%

        Looking for more information?